Aloe Vera for Blood Sugar and Metabolic Health
A modest but real body of small clinical trials suggests that oral aloe vera gel can lower fasting blood glucose and hemoglobin A1c (HbA1c), with signals reported in both prediabetes and type 2 diabetes. Several trials also report small improvements in cholesterol and triglycerides. These are genuinely interesting findings — but the trials are small, short, and inconsistent, the aloe products are poorly standardized, and there are no long-term or hard-outcome data. This page lays out what the meta-analyses show, why the evidence is still uncertain, and what is known about its safety alongside diabetes medicines.
Table of Contents
- The Short Version
- Gel Versus Latex
- Proposed Mechanisms
- Prediabetes and Early Type 2 Diabetes
- Established Type 2 Diabetes
- Cholesterol and Triglycerides
- Metabolic Syndrome and Weight
- Why the Evidence Is Still Weak
- Practical Use and Monitoring
- Cautions and Drug Interactions
- Key Research Papers
- Connections
- Featured Videos
The Short Version
Pooled analyses of randomized trials suggest oral aloe gel lowers fasting glucose by a clinically meaningful amount in people with impaired glucose control, and modestly lowers hemoglobin A1c, in both prediabetes and type 2 diabetes. The effect appears smaller or absent in people whose diabetes is already well managed on medication. Because the trials are small and heterogeneous, professional bodies do not recommend aloe as a treatment for diabetes — it is, at most, a possible complementary aid alongside diet, exercise, and prescribed medication.
Gel Versus Latex
Every metabolic trial worth citing used purified inner-leaf gel or a standardized extract, not aloe latex. The latex is a stimulant laxative with genotoxicity and other safety concerns, and it is not the form the blood-sugar trials tested. In 2-year U.S. National Toxicology Program studies in rats and mice, whole-leaf aloe extract that had not been decolorized, given by mouth, produced intestinal tumours (an animal finding; Dunnick and Nyska 2013). Inner-leaf products sold for oral use are labelled decolorized and low in aloin, some certified by an industry trade association. The Digestive Health page explains the gel-versus-latex distinction in detail.
Proposed Mechanisms
Several mechanisms have been proposed, mostly from animal and laboratory work:
- Phytosterols. Aloe gel contains phytosterols such as lophenol and cycloartanol that improved glucose and lipid handling in diabetic animal models, apparently by enhancing insulin sensitivity.
- Polysaccharides and delayed absorption. The viscous polysaccharide matrix (including acemannan) may slow gastric emptying and glucose absorption, blunting post-meal spikes.
- Antioxidant and anti-inflammatory effects that could, in theory, ease the oxidative stress and low-grade inflammation of insulin resistance.
These mechanisms are plausible but not firmly established in humans; the honest position is that we observe a glucose-lowering signal in trials without fully understanding why.
Prediabetes and Early Type 2 Diabetes
A 2016 systematic review and meta-analysis by Suksomboon and colleagues (8 trials, 470 patients) found that aloe improved glycaemic control in prediabetes and type 2 diabetes. In prediabetes it lowered fasting plasma glucose by 0.22 mmol/L but had no effect on HbA1c; in type 2 diabetes it gave a marginal fall in fasting glucose (1.17 mmol/L, P = 0.05) and a significant fall in HbA1c (11 mmol/mol, P = 0.01). A separate 2016 meta-analysis by Zhang and colleagues focusing on prediabetes and early, non-treated diabetic patients (5 trials, 415 participants) found that fasting blood glucose fell by 30.05 mg/dL and HbA1c by 0.41%, with lower triglycerides, total cholesterol and LDL cholesterol; the authors called the results inconclusive because of the small number and poor quality of the trials. A randomized controlled trial by Alinejad-Mofrad and colleagues in 72 people with prediabetes compared aloe capsules of 300 mg or 500 mg twice a day with placebo for 8 weeks: the 300 mg dose lowered fasting blood glucose by week 4 and HbA1c by week 8, and the 500 mg dose lowered total and LDL cholesterol. Devaraj and colleagues, in an 8-week pilot trial of 45 people with prediabetes and metabolic syndrome, reported that two aloe inner-leaf gel powders each lowered fasting glucose and fructosamine. These studies do not show one consistent pattern of a bigger benefit before medication is started: in the Suksomboon analysis the HbA1c effect was seen in type 2 diabetes but not in prediabetes, and in the Dick analysis (next section) people starting with the highest fasting glucose had the largest fall. For the condition, see our Prediabetes page.
Established Type 2 Diabetes
A 2016 meta-analysis by Dick and colleagues pooled 9 studies of oral aloe in people with prediabetes and diabetes (283 people): fasting glucose fell by 46.6 mg/dL, and HbA1c fell by 1.05% in the 5 studies that measured it (89 people). People starting with a fasting glucose of 200 mg/dL or more had a larger fall (109.9 mg/dL), and the authors found signs of publication bias in the fasting-glucose result but not in the HbA1c result. A 2021 overview of four systematic reviews by Araya-Quintanilla and colleagues concluded that there is moderate- to high-quality evidence in favour of aloe's effects on fasting glucose and HbA1c in type 2 diabetes and prediabetes. A 2021 overview of 25 meta-analyses by Willcox and colleagues ranked aloe vera leaf gel first of 18 plant remedies for lowering HbA1c in type 2 diabetes (mean difference -0.99%, 95% confidence interval -1.75 to -0.23). These trials were short, and aloe has not been tested as a replacement for metformin, other medications, or lifestyle therapy. See our Type 2 Diabetes page and Insulin Resistance page.
Cholesterol and Triglycerides
Some of the same trials that measured glucose also reported small reductions in total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides with oral aloe, particularly in people with prediabetes or metabolic syndrome. The lipid findings are less consistent than the glucose findings and, again, come from small studies. Aloe is not a substitute for statin therapy where that is indicated, but a favorable nudge in lipids is a plausible secondary effect of improving overall metabolic health.
Metabolic Syndrome and Weight
A 2019 narrative review by Shakib and colleagues summarized aloe's potential role in metabolic syndrome, drawing together the glucose, lipid, and anti-inflammatory strands. A few trials have reported small reductions in body weight or fat mass, but the data are too limited to consider aloe a weight-loss agent. The realistic framing is that aloe might modestly support the cluster of metabolic-syndrome measures (glucose, lipids, possibly weight) as one small piece of a diet-and-exercise-centered plan. See our Metabolic Syndrome page.
Why the Evidence Is Still Weak
It is worth being explicit about the weaknesses, because the marketing rarely is:
- Small samples and short duration. Most trials enrolled a few dozen people for 4 to 12 weeks — too short to know whether any benefit lasts or affects real outcomes such as heart attacks or kidney disease.
- Product heterogeneity. "Aloe" varied from gel to powdered extract to standardized preparations, at different doses, making results hard to compare.
- Risk of bias. Many studies had incomplete blinding or reporting, and small positive trials of supplements are more likely to be published than null ones.
- Heterogeneity and trial quality. The meta-analysis authors flag the limits themselves: Suksomboon 2016 pointed to high heterogeneity in study results, and Zhang 2016 called its results inconclusive given the small number and poor quality of the trials. The 2021 overview by Araya-Quintanilla rated the evidence more favourably, as moderate to high quality.
None of this means aloe does nothing — the signal is fairly consistent — but the size and durability of the effect remain uncertain.
Practical Use and Monitoring
- Products in the trials. The trials used purified inner-leaf gel or standardized extracts; inner-leaf products are sold labelled decolorized and low in aloin, some certified by an industry trade association.
- Glucose readings. In people taking insulin or oral hypoglycemics, aloe can add to their effect; low blood sugar (hypoglycemia) shows as shakiness, sweating and confusion, and blood-sugar readings in the first weeks show whether the combination is pushing glucose low.
- Prescribed medication. No trial has tested aloe as a replacement for prescribed medication or lifestyle therapy.
- Drug doses. Because aloe adds to the effect of glucose-lowering drugs (fasting glucose fell by 46.6 mg/dL on average in the Dick 2016 analysis), readings that fall meaningfully can mean those drug doses are now too high; kidney and liver blood tests are how harm to those organs is detected.
- Trial length. Most studies ran 4 to 12 weeks, and their effects showed up within that time (fasting glucose fell by week 4 in one prediabetes trial).
Cautions and Drug Interactions
- Additive hypoglycemia with insulin, sulfonylureas, and other glucose-lowering drugs — the main interaction reported.
- Surgery. Because aloe can affect blood glucose, it is often advised to stop it about two weeks before scheduled surgery.
- Latex form. Its laxative-driven potassium loss can be dangerous with digoxin and diuretics.
- Pregnancy and breastfeeding — there is no good safety data for oral aloe in pregnancy and breastfeeding; the latex is a stimulant laxative.
- Kidney disease — there is no good safety data for oral aloe in advanced chronic kidney disease (CKD); the two effects that matter are the latex's laxative-driven potassium loss and aloe's added glucose lowering.
Key Research Papers
- Suksomboon N, Poolsup N, Punthanitisarn S (2016). Effect of Aloe vera on glycaemic control in prediabetes and type 2 diabetes: a systematic review and meta-analysis. J Clin Pharm Ther — PubMed PMID: 27009750
- Dick WR, Fletcher EA, Shah SA (2016). Reduction of fasting blood glucose and hemoglobin A1c using oral aloe vera: a meta-analysis. J Altern Complement Med — PubMed PMID: 27152917
- Zhang Y, Liu W, Liu D, et al. (2016). Efficacy of aloe vera supplementation on prediabetes and early non-treated diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Nutrients — PubMed PMID: 27347994
- Alinejad-Mofrad S, Foadoddini M, Saadatjoo SA, Shayesteh M (2015). Improvement of glucose and lipid profile status with Aloe vera in pre-diabetic subjects: a randomized controlled-trial. J Diabetes Metab Disord — PubMed PMID: 25883909
- Devaraj S, Yimam M, Brownell LA, et al. (2013). Effects of Aloe vera supplementation in subjects with prediabetes/metabolic syndrome. Metab Syndr Relat Disord — PubMed PMID: 23035844
- Araya-Quintanilla F, Gutierrez-Espinoza H, et al. (2021). Effectiveness of aloe vera in patients with type 2 diabetes mellitus and pre-diabetes: an overview of systematic reviews. Diabetes Metab Syndr — PubMed PMID: 34563809
- Shakib Z, Shahraki N, Razavi BM, Hosseinzadeh H (2019). Aloe vera as an herbal medicine in the treatment of metabolic syndrome: a review. Phytother Res — PubMed PMID: 31456283
- Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS (2003). Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care — PubMed PMID: 12663610
- Willcox ML, Elugbaju C, Al-Anbaki M, et al. (2021). Effectiveness of medicinal plants for glycaemic control in type 2 diabetes: an overview of meta-analyses of clinical trials. Front Pharmacol — PubMed PMID: 34899340
- Dunnick JK, Nyska A (2013). The toxicity and pathology of selected dietary herbal medicines. Toxicol Pathol — PubMed PMID: 23262639
- Cefalu WT, Ye J, Wang ZQ (2008). Efficacy of dietary supplementation with botanicals on carbohydrate metabolism in humans. Endocr Metab Immune Disord Drug Targets — PubMed PMID: 18537692